

## **CURRICULUM VITAE**

**Mark Richard Vesely, M.D.**

Associate Professor, Department of Medicine  
Division of Cardiovascular Medicine, Interventional Cardiology Section  
University of Maryland School of Medicine

**Date**            Oct 1, 2016

### **Contact Information**

Business Address:                    110 South Paca Street, 7<sup>th</sup> Floor  
   Baltimore, MD 21201  
Business Phone:                      (410) 328-1044  
Fax Number:                            (410) 328-7241  
Email:                                    mvesely@medicine.umaryland.edu

### **Education**

1991-1994    Bachelor of Science, Biochemistry  
   Trinity College, Hartford, CT  
  
1997-2001    Doctor of Medicine  
   George Washington University School of Medicine, Washington, DC

### **Post Graduate Education and Training**

2001-2004    Internship and Residency: Internal Medicine  
   Dept Internal Medicine, University of Maryland Medical Center, Baltimore, MD  
  
2004-2007    Clinical Fellowship: Cardiovascular Disease  
   Division of Cardiology, University of Maryland Medical Center, Baltimore, MD  
  
2007-2008    Clinical Fellowship: Interventional Cardiology  
   Division of Cardiology, University of Maryland Medical Center, Baltimore, MD

### **Certifications**

2004            Diplomat, American Board of Internal Medicine  
2007            Diplomat, ABIM, Cardiovascular Disease  
2008            Diplomat, ABIM, Interventional Cardiology  
2008            Diplomat, Certification Board of Nuclear Cardiology

### **Medical Licensures**

2008-present    Maryland Board of Physicians

### **Employment History**

#### **Academic Appointments**

2004-2008    Assistant Instructor of Medicine  
   University of Maryland School of Medicine, Baltimore, MD (UMSOM)

2008- 2016 Assistant Professor, Department of Medicine  
UMSOM

2016-present Associate Professor, Department of Medicine  
UMSOM

### **Other Employment**

1994- 1997 Research Technician  
Department of Cardiology/Division of Genetics  
Children's Hospital/Harvard Medical School, Boston, MA

1998 - 2000 Research Assistant  
Children's Research Institute  
Children's National Medical Center, Washington, DC

### **Professional Society Memberships**

2008-present Fellow, American College of Cardiology

2008-present Fellow, Society for Cardiovascular Angiography & Interventions

2012-present Member, American Heart Association

### **Honors and Awards**

1994 Thomas H. Bissonnette Teaching Fellowship  
Trinity College, Hartford, CT

1994 Graduated with Honors in Biochemistry  
Trinity College, Hartford, CT

1998 3rd Place Poster, 63rd Annual William Beaumont Research Day  
George Washington University School of Medicine, Washington, DC

1998 *Member, William Beaumont Honorary Research Society*  
George Washington University School of Medicine, Washington, DC

1999 Tauber Scholar  
George Washington University School of Medicine, Washington, DC

2007 Nathan H. Carliner, M.D. Scholar Award  
Division of Cardiology, UMDSOM, Baltimore, MD

2013 2013 *Super Doctors® Rising Stars*  
Cardiology: Washington, DC – Baltimore – Northern Virginia region  
Limited to 2.5% of regional physicians

## **Clinical Activities**

### **Clinical Expertise**

Invasive/Interventional Cardiology: Diagnostic cardiac catheterization  
Hemodynamics and Coronary Angiography  
Percutaneous Coronary Intervention  
Transcatheter Mitral Valve Repair  
Balloon Mitral Valvuloplasty  
Balloon Aortic Valvuloplasty  
Intra-aortic Balloon Pump  
Impella Ventricular Assist Device

Nuclear Cardiology: myocardial perfusion stress testing  
Cardiovascular Disease: general consultative and inpatient management  
Echocardiography

### **Scope of Clinical Practice**

2008-present Attending Physician, Cardiac Catheterization Laboratory, UMMC & BVAMC  
Diagnostic and Interventional Cardiology Procedures  
Currently: 9 hours/day, 5 days/week, 39 weeks/year

2008-present General Cardiology Outpatient Practice  
University of MD Cardiology Physicians at Westminster, Westminster, MD  
Currently: 3 hours/day, 5 days/week, 13 weeks/year

2008-present Inpatient / Interventional Cardiology Services  
Carroll Hospital Center, Westminster, MD  
Currently: 6 hours/day, 5 days/week, 13 weeks/year

2008-present Interventional Cardiology Call Coverage: UMMC and Carroll Hospital Center  
Currently: 1-2 weeknights/week and 1-2 weekends/month, 52 weeks/year

### **Innovative Techniques and Program Development**

2013-present Multi-disciplinary Mitral Valve Program, University of Maryland Heart Center  
Only program in State of Maryland to offer commercially available Transcatheter  
Mitral Valve Repair with MitraClip® system

## **Administrative Service**

### **Institutional Service**

1999-2001 Medical Student Representative, Faculty Senate Research Advisory Committee  
George Washington University School of Medicine, Washington, DC

2006-2008 Fellow Representative, Cardiology Educational Task Force  
Division of Cardiology, UMDSOM, Baltimore, MD

- 2008-2013 Associate Program Director, Interventional Cardiology Fellowship  
University of Maryland School of Medicine, Baltimore, MD
- 2009-2010 Member, Cardiology Educational Task Force  
Division of Cardiology, UMDSOM, Baltimore, MD
- 2010 Member, Physician Advisory Group  
Office of Referring Physicians, UMMC, Baltimore, MD
- 2010-2011 Director, Return to Sender Initiative  
Division of Cardiology, UMDSOM, Baltimore, MD
- 2012- 2014 Member, School of Medicine Council  
UMDSOM, Baltimore MD
- 2012-present Member, General Clinical Research Center Advisory Committee  
UMDSOM, Baltimore MD
- 2013–present Program Director, Interventional Cardiology Fellowship Program  
University of Maryland School of Medicine, Baltimore, MD
- 2013–present Medical Director  
Cardiac Catheterization Laboratory  
Baltimore Veterans Administration Medical Center
- 2013-present Co-Chair, Pharmacogenomics Subcommittee  
Pharmacy and Therapeutics Committee  
University of Maryland Medical Center
- 2013-present Member, Radiation Safety Committee  
Baltimore Veterans Administration Medical Center

## **Local and National Service**

### **National Service**

- 2012 Session Moderator, Hybrid Treatment of Coronary Artery Disease  
Surgical, Interventional, & Hybrid Procedures Symposium: Coronary Intervention  
Transcatheter Cardiovascular Therapeutics (TCT) conference, Miami FL
- 2013 Ad Hoc Reviewer, *International Journal of Medical Sciences* (1x/yr)
- 2013 Abstract Reviewer, *Transcatheter Cardiovascular Therapeutics* conference
- 2015 Ad Hoc Reviewer, *Emergency Medicine Journal* (1x/yr)

- 2016 Ad Hoc Reviewer, *Journal of the American College of Cardiology (1x/yr)*
- 2015-present Member, Interventional Program Directors & Training Standards Committee  
Society of Coronary Angiography and Interventions
- 2015-present Member, Structural Heart Disease Committee  
Society of Coronary Angiography and Interventions
- 2015-present Member, Interventional Heart Failure Work Group  
Society of Coronary Angiography and Interventions

### **Local Service**

- 2010 Session Moderator, Integrated Cardiovascular Repair Workshop 2010  
Baltimore, MD
- 2013 Informational TV interview: Heart disease: Prevention and Treatment  
*Direct Connection with Jeff Salkin*  
Maryland Public Television

### **Teaching Service**

#### **Undergraduate Student Teaching**

- 1992-1993 Teaching Assistant: Organic Chemistry Laboratory  
Department of Chemistry, Trinity College, Hartford, CT
- 1994 Teaching Associate: Cells, Metabolism, and Heredity  
Department of Biology, Trinity College, Hartford, CT

#### **Medical Student Teaching**

- 2000-2001 Mentor to First Year Medical Students, Teaching Interview & Physical Exam  
MSIV medical student elective: *The Clinician as Medical Educator*  
George Washington University School of Medicine, Washington, DC
- 2004-2008 Introduction to Clinical Medicine, UMSOM  
Small Group Teaching  
10-15 hrs/year, 2-4 medical students/group

#### **Resident and Fellow Teaching**

- 2004 - 2008 Fellow, Inpatient CCU service  
University of Maryland Medical Center  
2 months/year, 1-3 MS (MS III and MS IV), 4 Residents
- 2004-2008 Fellow, Cardiology Consult Service  
University of Maryland Medical Center  
2 months/year, 1-3 MS (MS III and MS IV), 4 Residents

2008 - present Attending Physician, Cardiac Catheterization Laboratory  
2 Interventional Cardiology Fellows, 2-3 General Cardiology Fellows  
9 hours/day, 5 days/week, 39 weeks/year

### **Grant and Contract Support**

#### **Active Grants:**

07/01/16-06/30/17 (PI, 0%)  
*Training Grant: Interventional Cardiology Fellowship Program.*  
*To fund educational materials and activities for current trainees.*  
Industry sponsor: Medtronic  
Total Direct Costs: \$22,000

#### **Completed Grants:**

09/01/10-08/31/2015 (Co-investigator, 10%) PI: A. Shuldiner  
“Translational Pharmacogenomics Project”  
NIH U01HL105198-06  
Total Costs (Direct + Indirect; 5-year study): \$13,557,37  
*Role: subject recruitment, Cardiology expertise*

07/01/13-06/30/14 (PI, 0%)  
*Training Grant to support Interventional Cardiology Fellowship Program.*  
*Funds dedicated for support of salary costs for current trainees.*  
Industry sponsor: Boston Scientific Corporation

07/01/15-06/30/16 (PI, 0%)  
*Training Grant: Interventional Cardiology Fellowship Program.*  
*Funds dedicated for support of salary costs for current trainees.*  
Industry sponsor: Medtronic  
Total Direct Costs: \$22,000

#### **Active Contracts:**

07/01/09-present (Site-PI, 0%)  
“A Phase II, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL® (ex vivo cultured adult human mesenchymal stem cells) intravenous infusion following acute myocardial infarction”  
Industry sponsored multi-center trial: Osiris Therapeutics, Inc.  
Total Costs (Direct + Indirect): \$413,462

10/01/10-present (Co-investigator, 0%); PI: P. Reyes  
“ALERTS: AngelMed for Early Recognition and Treatment of STEMI”  
Industry sponsored multi-center trial: Angel Medical Systems  
Total Costs (Direct + Indirect): \$136,197  
*Role: subject recruitment and follow up care*

- 04/01/12-present (Site-PI, 0%)  
 “PreSERVE-AMI Study: A Prospective randomized double blinded placebo controlled phase II trial of intra-coronary infusion of AMR001, a bone marrow derived autologous CD34+ selected cell product in patients with acute myocardial infarction.”  
 Industry sponsored multi-center trial: Amorcey, Inc.  
 Total Costs (Direct + Indirect): \$372, 815
- 10/01/13-present (Site Co-PI, 0%)  
 “COAPT: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation”  
 Industry sponsored multi-center trial: Evalve, Abbott Vascular  
 Total Costs (Direct + Indirect): \$157,000

### **Completed Contracts:**

- 02/01/09-09/30/11 (Co-investigator, 0%); PI: P. Reyes  
 “TRACER: Trial to Assess the Effects of SCH530348 in Preventing Heart Attack and Stroke in Patients with Acute Coronary Syndrome”  
 Industry sponsored multi-center trial: Schering-Plough  
 Total Direct Costs: \$199, 550  
*Role: subject recruitment and follow up care*
- 05/01/09-03/31/12 (Co-investigator, 0%); PI: P. Reyes  
 “TIMI-50: Trial to Assess the Effects of SCH530348 in Preventing Heart Attack and Stroke in Patients with Atherosclerosis”  
 Industry sponsored multi-center trial: Schering-Plough  
 Total Direct Costs: \$55, 933  
*Role: subject recruitment and follow up care*
- 09/01/10-08/31/12 (Co-investigator, 0%); PI: J. Bonatti  
 “Hybrid Revascularization Observational Study”  
 NIH/NHLBI sponsored multi-center trial, sub-contract  
 Total Direct Costs: \$20,200  
*Role: subject recruitment and Interventional Cardiology expertise*  
 Total Direct Costs: \$20,000

### **Publications**

#### **Peer Reviewed Journal Articles**

1. Benson DW, MacRae CA, Vesely MR, Walsh EP, Seidman JG, Seidman CE, Satler CA  
 Missense mutation in the pore region of HERG causes familial long QT syndrome.  
 Circulation 1996; 93(10):1791-5.

2. Satler CA, Walsh EP, **Vesely MR**, Plummer MH, Ginsburg GS, Jacob HJ. Novel missense mutation in the cyclic nucleotide-binding domain of HERG causes long QT syndrome. *Am J of Med Genet* 1996; 65(1):27-35.
3. Prigodich RV, **Vesely MR**. Characterization of the complex between bovine osteocalcin and type I collagen. *Arch Biochem Biophys* 1997; 345(2):339-41
4. Duggal P, **Vesely MR**, Wattanasirichaigoon D, Villafane J, Kaushik V, Beggs AH. Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of long QT syndrome. *Circulation* 1998; 97(2):142-6
5. Satler CA, **Vesely MR**, Duggal P, Ginsburg GS, Beggs, AH. Multiple different missense mutations in the pore region of HERG in patients with long QT syndrome. *Human Genet* 1998; 102(3): 265-72
6. Wattanasirichaigoon D, **Vesely MR**, Duggal P, Levine JC, Blume ED, Wolff GS, Edwards SB, Beggs AH. Sodium channel abnormalities are infrequent in patients with long QT syndrome: identification of two novel SCN5A mutations. *Am J Med Genet.* 1999 Oct 29;86(5):470-6.
7. Mehra MR, Uber PA, Walther D, **Vesely MR**, Wohlgemuth JG, Prentice J, Tayama D, Billingham M. Gene Expression Profiles And B-Type Natriuretic Peptide Elevation In Heart Transplantation: More Than A Hemodynamic Marker. *Circulation.* 2006 Jul 4;114(1 Suppl):I21-6.
8. Gottlieb SS, Kop WJ, Thomas SA, Katzen S, **Vesely MR**, Greenberg N, Marshall J, Cines M. A double-blind placebo controlled pilot study of controlled release paroxetine on depression and quality of life in chronic heart failure. *Am Heart J.* 2007 May;153(5):868
9. **Vesely MR**, Li S, Kop W, Reese A, Marshall J, Shorofsky SR, Gottlieb SS, Mehra MR, Gottdiener JG. Test-retest Reliability of Assessment for for Intraventricular Dyssynchrony By Tissue Doppler Echocardiography. *Am J Cardiol.* 2008 Mar 1;101(5): 645-650
10. **Vesely MR**, Dilsizian V. Nuclear Cardiac Stress Testing in the Era of Molecular Medicine. *J Nucl Med.* 2008 Mar; 49(3): 399-413
11. Schwartz DJ, Kop WJ, Park MH, **Vesely MR**, Li S, Mehra MR, Gottdiener JS. Evidence for early right ventricular and septal mechanical activation (Interventricular dyssynchrony) in pulmonary hypertension. *Am J Cardiol.* 2008 Nov1;102(9):1273-7
12. Rehman A, Garcia J, Deshpande S, Odonkor P, Reicher B, **Vesely M**, Zimrin D, Griffith B, Bonatti, J. Totally endoscopic coronary artery bypass grafting is feasible in morbidly obese patients. *Heart Surg Forum.* 2009 Jun;12(3):E134-6
13. Bonatti J, Lehr E, **Vesely MR**, Friedrich G, Bonaros N, Zimrin D. Hybrid coronary revascularization:which patients? When? How? *Curr Opin Cardiol.* 2010Nov;25(6):568-74.
14. Lehr EJ, Zimrin D, **Vesely M**, Odonkor P, Griffith B, Bonatti J. Axillary-coronary sequential vein graft for total endoscopic triple coronary artery bypass. *Ann Thorac Surg.* 2010 Nov;90(5):e79-81.
15. Zimrin D, Bonatti J, **Vesely MR**, Lehr, EJ. Hybrid Coronary Revascularization: An Overview of Options for Anticoagulation and Platelet Inhibition. *Heart Surg Forum.* 2010 Dec 1; 13(6): E405-8



16. Beitelshes A, Horenstein R, **Vesely M**, Mehra M, Shuldiner AR. Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions. *Clin Pharmacol Ther.* 2011 Mar; 89(3):455-9
17. **Vesely MR**, Dilsizian V. Microvascular Angina: Assessment of Coronary Blood Flow, Flow Reserve, and Metabolism. *Curr Cardiol Rep.* 2011 Apr;13(2):151-8
18. Bonatti J, Lehr EJ, **Vesely M**, Friedrich G, Schachner T, Bonaros N, Griffith B, Zimrin D. Hybrid Coronary Revascularization – Techniques and Outcome. *European Surgery.* 2011; 43(4) 198-204
19. Wiedemann D, Bonaros N, Schachner T, Weidinger F, Lehr EJ, **Vesely M**, Bonatti J. Surgical Problems and Complex Procedures: Issues for Operative Time in Robotic Totally Endoscopic Coronary Artery Bypass Grafting. *J Thorac Cardiovasc Surg.* 2012 Mar; 143(3):639-47
20. Shuldiner AR, **Vesely MR**, Fisch A. CYP2C19 Genotype and Cardiovascular Events. *JAMA.* 2012 Apr; 307(14):1482
21. **Vesely MR**, Lee JD, Zimrin D, Bonatti J. Advanced Hybrid Coronary Revascularization (HCR) using Robotic Totally Endoscopic Triple Bypass Surgery and Left Main Percutaneous Intervention. *J Thorac Cardiovasc Surg.* 2012 Oct; 144(4):986-7
22. Bonatti J, Zimrin D, Lehr EJ, **Vesely MR**, Kon Z, Wehman B, DeBiasi A, Hofauer B, Weidinger F, Schachner T, Bonaros N, Friedrich G. Hybrid Coronary Revascularization Using Robotic Totally Endoscopic Surgery – Perioperative Outcome and 5-Year Results. *Ann Thorac Surg.* 2012 Dec (94):1920-6. PMID 23103003
23. Bonaros N, Schachner T, Lehr E, Kofler M, Wiedemann D, Hong P, Wheman B, Zimrin D, **Vesely M**, Friedrich G, Bonatti J. Five Hundred cases of Robotic Totally Endoscopic Coronary Artery Bypass Grafting: Predictors of Success and Safety. 2013 Mar;95:803-12. PMID 23312792
24. Shuldiner AR, Relling MV, Peterson JF, Hicks JK, ..., **Vesely M**, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. *Clin Pharmacol Ther.* 2013 Aug;94(2):207-10. PMID 23588301
25. Weidinger F, Schachner T, Bonaros N, Hofauer B, Lehr EJ, **Vesely M**, Zimrin D, Bonatti J. Predictors and consequences of postoperative atrial fibrillation following robotic totally endoscopic coronary bypass surgery. *Eur J Cardiothorac Surg.* 2014 Feb;45(2):318-22. PMID 23704711
26. Srivastava M, **Vesely MR**, Lee J, Lehr E, Wehman B, Bonaros N, Schachner T, Friedrich G, Zimrin D, Bonatti J. . Robotically-Assisted Hybrid Coronary Revascularization: Does Sequence of Intervention Matter? *Innovations: Technology and Techniques in Cardiothoracic and vascular Surgery.* 2013 May-Jun;8(3):177-83. PMID 23989810
27. Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, ..., **Vesely MR**. Implementation of pharmacogenetics: The University of Maryland personalized anti-platelet pharmacogenetics program. *Am J Med Genet C Semin Med Genet.* 2014 Mar;166(1):76. PMID 24616408
28. Bonaros N, Schachner T, Kofler M, Lehr E, Lee J, **Vesely M**, Zimrin D, Feutchner G, Friedrich G, Bonatti J. Advanced hybrid closed chest revascularization: an innovative strategy for the treatment of multivessel coronary artery disease. *Eur J Cardiothorac Surg.* 2014 Dec;46(6):e94-102. PMID 25256825

29. **Vesely MR**, Benitez RM, Robinson SW, Collins JA, Dawood MY, Gammie JS. Surgical and Transcatheter Mitral Valve Repair for Severe Chronic Mitral Regurgitation: A review of clinical indications and patient assessment. *J Am Heart Assoc.* 2015 Dec 11;4(12): 1-8. PMID 26656862
30. Puskas J, Halkos, M, DeRose JJ, Bagiella E, Miller M, Overbey J, Bonatti J, **Vesely M**, Sutter F, Lynch J, Kirkwood K, Shapiro T, Boudoulas K, Crestanello J, Gehrig T, Smith P, Ragosta M, Hoff S, Zhao D, Gelijns A, Szeto W, Weisz G, Argenziano M, Liberman H, Matthai W, Ascheim D. Hybrid Coronary Revascularization for the Treatment of Multi-vessel Coronary Artery Disease: A Multi-Center Observational Study. *J Am Coll Cardiol.* 2016 Jul 26;68(4): 356-65. PMID 27443431

### **Submitted or In-Revision Peer Reviewed Journal Articles**

1. Watkins AC, Wehman B, **Vesely MR**, Griffith BP. The Effects of Combined Mesenchyma and Cardiac Stem Cell Therapy in a Porcine Model of Ischemic Cardiomyopathy: Early Findings. *J Thorac Cardiovasc Surg.* *Submitted June 2015.*

### **Non-Peer Reviewed Journal Articles**

1. **Vesely MR** and Kelemen MD. Cardiac Risk Assessment: Matching Intensity of Therapy to Risk. In: *Cardiology Clinics of North America.* *Cardiol Clin.* 2006;24(1):67-78
2. Mistry N, **Vesely MR**. Acute Coronary Syndromes: From ED to the CCU. *Cardiol Clin.* 2012 Nov; 30(4):617-27

### **Book Chapters**

1. **Vesely MR**, Arrighi JA, Gurm GS, Kommana H, Dilsizian V. *Post-MI Risk Stratification*, in *Multimodality Imaging in Cardiovascular Medicine.* C.M. Kramer, Editor. 2010, Demos Medical: New York. p. 71-91
2. Srivastava M, Zimrin D, Taylor B, **Vesely MR**. *Hybrid coronary revascularization: an overview of options for anticoagulation and platelet inhibition in Robotic Cardiac Surgery.* C. Gao, Editor. 2013, Springer

### **Abstracts and/or Proceedings**

#### **Poster Presentations**

- 1998      *A complete analysis of the HERG gene coding sequence for LQTS-associated mutations* 63<sup>rd</sup> Annual William Beaumont Research Day, Washington, DC
- 2002      *Clinical Vignette: Sarcoidosis in an 80 year old male*  
*Chapter Scientific Meeting, Maryland Chapter, ACP-ASIM, Baltimore, MD*
- 2010      Pollock J, Perrin P, Lakin C, Grant M, **Vesely M**, Poston R, Zimrin D. *Five-Year Mortality for Hybrid Coronary Revascularization versus CABG*  
*Integrated Cardiovascular Repair Workshop 2010, Baltimore, MD*

- 2010 Lehr EJ, Bonaros N, Schachner T, Wiedemann D, Weidinger F, **Vesely M**, Zimrin D, Griffith B, Bonatti J. *Hybrid treatment of multivessel coronary artery disease using robotic surgical techniques*. Canadian Cardiovascular Conference 2010. Montreal, Canada
- 2013 **Vesely MR**, Lehr EJ, Bonaros N, Schachner T, Friedrich G, Kofler M, Srivastava M, Zimrin D, Bonatti J. *Predictors of Long Term Outcomes in Hybrid Coronary Revascularization*. College of Cardiology Scientific Sessions, San Francisco, CA
- 2013 DeRose JJ, Liberman H, Matthai W, Szeto W, Parides M, Srinivas V, Bonatti J, Overbey J, **Vesely M**, Sutter F, Williams P, Shapiro T, Crestanello J, Boudoulas K, Smith P, Gehrig T, Ailawadi G, Davidson M, Zhao D, Argenziano M, Williams M, Puskas J, Halkos M, Ascheim D. *Interventional Cardiologists and Cardiac Surgeons: Concordance Regarding Anatomic Eligibility for Hybrid Coronary Revascularization in >6,500 Patients*. American College of Cardiology Scientific Sessions, San Francisco CA

### **Oral Presentations**

- 1997 *Complete analysis of the HERG gene for mutations in long QT syndrome*  
American Heart Association, 68<sup>th</sup> Scientific Sessions, Orlando, FL
- 2003 *Hypothermia inhibits Fas-mediated apoptosis in lung epithelial cells*  
Chapter Scientific Meeting, Maryland Chapter, ACP-ASIM, Baltimore, MD
- 2004 *Management of End-Stage Heart Failure*. Senior Resident Talk  
Department of Internal Medicine, UMMS, Baltimore, MD
- 2013 Puskas JD, Ascheim D, Halkos M, Bagiella E, DeRose J, Miller M, Kirkwood K, Bonatti J, Srinivas V, **Vesely M**, Sutter F, Lynch J, Shapiro T, Boudoulas K, Crestanello J, Gehrig T, Smith P, Ragosta M, Hoff S, Zhao D, Gelijns A, Szeto W, Weisz G, Argenziano M, Matthai W. *Hybrid Coronary Revascularization for the Treatment of Coronary Artery Disease: A Multicenter Observational Study*. American College of Cardiology Scientific Sessions, San Francisco CA

### **Major Invited Talks**

#### **Local**

1. Hybrid Coronary Revascularization: A Model for Interdisciplinary Treatment of Coronary Artery Disease Robotic Cardiovascular Revascularization Symposium Hatton Institute, Good Samaritan Hospital, Cincinnati OH, 2009
2. Intravenous Human Mesenchymal Stem Cells Following Acute Myocardial Infarction Maryland Stem Cell Research Symposium, Gaithersburg, MD, 2010
3. Stem Cell Therapies for Ischemic Heart Disease Medicine Grand Rounds, University of Maryland School of Medicine, 2011
4. Translational Pharmacogenetics Project: Logistics of Personalized Dual Anti-Platelet Therapy, CYP2C19 based Variability of Clopidogrel Activation Cardiology Grand Rounds, University of Maryland School of Medicine, Baltimore MD, 2013
5. Transcutaneous Approaches for Treatment of Mitral Regurgitation. 2015 Kyle Y. Swisher Day of Cardiology. St. Agnes Hospital. Baltimore MD. November, 2015

**National**

6. Hybrid Coronary Revascularization - The Interventionalist Perspective American College of Cardiology Scientific Sessions, Atlanta GA, 2010
7. Case Presentation: Robotic Hybrid CABG/PCI Case American Association of Thoracic Surgery, Philadelphia PA, 2011
8. Hybrid Coronary Revascularization: An Interventional Cardiologist Perspective Society of Thoracic Surgeons 48<sup>th</sup> Annual Meeting, Fort Lauderdale FL, 2012
9. Hybrid Coronary Revascularization: The University of Maryland Experience Transcatheter Cardiovascular Therapeutics (TCT) conference, Miami FL, 2012
10. Pharmacogenetic Derived Personalization of Dual Anti-Platelet Therapy: CYP2C19 Based Variability of Clopidogrel Activation. AVA Heart Symposium. Veterans Administration MC, Washington DC, 2013